Replimune says FDA grants accelerated approval for TUDRIQEV plus nivolumab in advanced melanoma after anti-PD-1 progression

PUBT · 1d ago
Replimune says FDA grants accelerated approval for TUDRIQEV plus nivolumab in advanced melanoma after anti-PD-1 progression
  • FDA granted accelerated approval for Replimune’s TUDRIQEV with nivolumab in unresectable advanced cutaneous melanoma progressing on anti-PD-1 therapy.
  • Approval based on IGNYTE objective response rate of 24.2% with median duration of response of 14.1 months.
  • Continued approval hinges on confirmatory evidence; Phase 3 IGNYTE-3 trial is ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061600PRIMZONEFULLFEED9805597) on August 06, 2026, and is solely responsible for the information contained therein.